Ovarian carcinoma have
been classified into 5 distinct grade groups based on histopathology and
molecular genetic alterations, high-grade Serous are said to be about 70%,
endometrioid 10%, clear cell 10%, Mucinous 3%, and low-grade Serous carcinomas
<5% according to studies by Prat et
al (Jaime Prat, 2012). In this study
we found 44.4% of Serous carcinoma with P53 high/overexpression, 11.1% of
Serous carcinoma with P53 negative expression and Serous carcinoma with wild
type P53 expression. There were 18.5% of Mucinous carcinoma cases. One case 3.7%
was reclassified as Endometrioid carcinoma(Jaime Prat, 2012). We did not
find any case of Clear cell carcinoma. Therefore HGSCs are still the most
common malignant EOTs with high/over expression of p53. These group have varied
epidemiological and genetic risk factors, as well as precursor lesions and
molecular events during oncogenesis, response to chemotherapy, and prognosis. Mutations causing
loss of wild-type p53 function due to either gain of abnormal function of
mutant p53 or absent or low mutant p53 are usually associated with the
aggressive behavior of this group and it is general accepted that both high and
low, or entirely absent, p53 expression correlates significantly with mutant
p53, while expression levels between these two extremes are thought to
represent wild-type p53(Marks, Berchuck, Pence, & Iglehart, 1991)(Cole et al., 2016). Therefore the 3 serous carcinoma cases with Negative P53
expression and High MD Anderson grade may be properly categorized as HGSC if
parallel p53 sequencing can be done to identify the type of mutant P53 and this
may increase the number of HGSC by 11.1% to a total of 55.5%. LGSC follows HGSC
with a frequency of 22.2% which is slighter higher than the Mucinous carcinoma
that constitute 18.5%. the frequency of endomatroid carcinoma are the least
common and can often be missed diagnosed if strict adherence to the WHO
classification of EOTs is not taken because, there may be many squamoid areas
mimicking and adenocarcinoma.